Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 201 to 225 of 1146 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
914 decreased fibrinolysis (GO:0042730) 1846: Thrombosis and Disseminated Intravascular Coagulation
916 decreased succinate dehydrogenase activity (GO:0000104) 2118: Succinate dehydrogenase, inhibited
917 decreased FAD metabolic process (GO:0046443) succinate dehydrogenase complex (GO:0045281) 2118: Succinate dehydrogenase, inhibited
918 decreased succinate metabolic process (GO:0006105) succinate dehydrogenase complex (GO:0045281) 2118: Succinate dehydrogenase, inhibited
923 decreased signaling (GO:0023052) neurotransmitter (CHEBI:25512) 2151: Disruption, neurotransmitter release
936 decreased toll-like receptor 3 signaling pathway (GO:0034138) viral genome (GO:0019015) None
937 decreased toll-like receptor 7 signaling pathway (GO:0034154) influenzavirus NS gene translation product (PR:000044794) 2180: Immune mechanisms antagonized by viral proteins
938 decreased toll-like receptor 3 signaling pathway (GO:0034138) influenzavirus NS gene translation product (PR:000044794) 2180: Immune mechanisms antagonized by viral proteins
939 decreased sexual reproduction (GO:0019953) 2147: Decreased, Viable Offspring
940 decreased decreased body weight (MP:0001262) 864: Decreased, Body Weight
964 decreased viable offspring quantity (VT:1000181) 2147: Decreased, Viable Offspring
965 decreased hormone biosynthetic process (GO:0042446) None
967 decreased hormone biosynthetic process (GO:0042446) 17beta-Hydroxy-2-oxa-5alpha-androstan-3-one (CHEBI:79436) 1613: Decrease, dihydrotestosterone (DHT) levels
978 decreased interleukin-1 receptor activity (GO:0004908) interleukin-1 receptor type I (PR:000001363) 1700: Impaired IL-1R1 signaling in T cell
982 decreased impaired synaptic plasticity (MP:0001900) actin cytoskeleton of dendritic spine (GO:0098938) None
983 decreased postsynaptic actin cytoskeleton organization (GO:0098974) drebrin (PR:000006296) 2078: Loss of drebrin
987 decreased sodium:potassium-exchanging ATPase activity (GO:0005391) None
988 decreased import into cell (GO:0098657) sodium atom (CHEBI:26708) None
995 decreased neurogenesis (GO:0022008) 2098: Increase, Abnormal Neural Remodeling
1001 decreased bone mineralization (GO:0030282) 2090: Increase, Bone Remodeling
1004 decreased osteoblast differentiation (GO:0001649) 2089: Altered Bone Cell Homeostasis
1012 decreased sulfotransferase activity (GO:0008146) estrogen sulfotransferase (PR:000032783) 2155: Inhibition of Sulfotransferase E1 (SULT1E1)
1013 decreased sodium:potassium-exchanging ATPase activity (GO:0005391) sodium:potassium-exchanging ATPase complex (GO:0005890) 1562: Decreased Na/K ATPase activity
1014 decreased thyroid hormone transport (GO:0070327) monocarboxylate transporter 8 (PR:000014950) 2258: Inhibition, monocarboxylate transporter 8 (MCT8)
1015 decreased regulation of body fluid levels (GO:0050878) blood plasma (UBERON:0001969) None